Schultz, Martin http://orcid.org/0000-0002-1259-645X
Rasmussen, Line Jee Hartmann
Andersen, Malene H.
Stefansson, Jakob S.
Falkentoft, Alexander C.
Alstrup, Morten
Sandø, Andreas
Holle, Sarah L. K.
Meyer, Jeppe
Törnkvist, Peter B. S.
Høi-Hansen, Thomas
Kjøller, Erik
Jensen, Birgitte Nybo
Lind, Morten
Ravn, Lisbet
Kallemose, Thomas
Lange, Theis
Køber, Lars
Rasmussen, Lars Simon
Eugen-Olsen, Jesper
Iversen, Kasper Karmark
Funding for this research was provided by:
ViroGates A/S
Article History
Received: 3 July 2018
Accepted: 21 August 2018
First Online: 28 August 2018
Ethics approval and consent to participate
: The trial was approved by the board of directors at each participating hospital and the head of each participating department provided consent. The trial was presented to the Regional Ethics Committee, which decided that no formal approval was needed for this cluster-randomized study and in accordance with Danish law it could be conducted without consent of the patients (ref. no. FSP-15003590). At the start of the trial at least one other hospital performed suPAR analysis as a routine test. All processing of personal data followed national guidelines in accordance with Danish law, and the data access and processing were approved by the Danish Data Protection Agency (ref. no. HGH-2015-042, I-Suite 04087) and by the Danish Patient Safety Authority without explicit consent from the participants (ref. no. 3–3013-1744/1).
: Not applicable.
: MS, LJHR, MA, and JM have received funding for travel from ViroGates A/S, Denmark. JE-O is named as an inventor in patents for the use of suPAR as a prognostic biomarker. The patents are owned by Copenhagen University Hospital, Amager and Hvidovre, Denmark, and are licensed to ViroGates A/S. JE-O is co-founder, shareholder, and CSO of ViroGates A/S. The remaining authors have no conflicts of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.